Drägerwerk AG & Co. KGaA (SWX:DRW3)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.79B +75.3% |
| Revenue (ttm) | 3.30B +6.4% |
| Net Income | 158.11M +71.5% |
| EPS | 8.43 +71.5% |
| Shares Out | n/a |
| PE Ratio | 11.31 |
| Forward PE | 12.21 |
| Dividend | 2.08 (1.82%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 114.20 |
| Day's Range | n/a |
| 52-Week Range | 78.20 - 114.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departmen... [Read more]
Financial Performance
In 2025, Drägerwerk AG & Co. KGaA's revenue was 3.48 billion, an increase of 3.29% compared to the previous year's 3.37 billion. Earnings were 139.50 million, an increase of 12.13%.
Financial numbers in EUR Financial StatementsNews
Drägerwerk AG & Co. KGaA Q2 Earnings Call Highlights
Drägerwerk AG & Co. KGaA ETR: DRW3 reported higher sales, sharply improved earnings and a return to positive free cash flow in the first half of 2026, supported by demand across its safety business, i...
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q2 2026
Strong H1 2026 results with net sales up 7.7% and EBIT margin tripling to 4.0%. Safety division delivered robust growth and margins, while medical division improved but remained slightly negative. EBIT margin guidance raised to 6–8% for 2026, supported by customs refunds and resilient operations.
Drägerwerk AG & Co. KGaA Quarterly report: Q2 2026
Drägerwerk AG & Co. KGaA has published its Q2 2026 quarterly earnings report on July 30, 2026.
Drägerwerk AG & Co. KGaA Earnings release: Q2 2026
Drägerwerk AG & Co. KGaA released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Drägerwerk AG & Co. KGaA Slides: Q2 2026
Drägerwerk AG & Co. KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q1 2026
EBIT and Free Cash Flow rose sharply in Q1 2026, with strong sales growth and improved margins. Both divisions contributed to higher earnings, and guidance for the year remains positive, with no material impact expected from tariffs or geopolitical risks.
Drägerwerk AG & Co. KGaA Slides: Investor presentation
Drägerwerk AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
Drägerwerk AG & Co. KGaA Quarterly report: Q1 2026
Drägerwerk AG & Co. KGaA has published its Q1 2026 quarterly earnings report on April 30, 2026.
Drägerwerk AG & Co. KGaA Slides: Q1 2026
Drägerwerk AG & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Drägerwerk AG & Co. KGaA Earnings release: Q1 2026
Drägerwerk AG & Co. KGaA released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Drägerwerk AG & Co. KGaA Transcript: German Select VII Conference
The company reported record sales and margin growth in 2025, driven by strong operational performance and innovation in open medical ecosystems. Defense and Safety segments are set for significant expansion, while margin improvement will rely on top-line growth, pricing, and cost control.
Drägerwerk AG & Co. KGaA Slides: German Select VII Conference
Drägerwerk AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q4 2025
Record net sales and EBIT were achieved in 2025, with both divisions and all regions contributing to growth. Despite significant tariff and currency headwinds, profitability improved, and strong cash flow supported higher dividends and reduced debt.
Drägerwerk AG & Co. KGaA Annual report: Q4 2025
Drägerwerk AG & Co. KGaA has published its Q4 2025 annual report on March 24, 2026.
Drägerwerk AG & Co. KGaA Earnings release: Q4 2025
Drägerwerk AG & Co. KGaA released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Drägerwerk AG & Co. KGaA Annual report: Q4 2025
Drägerwerk AG & Co. KGaA has published its Q4 2025 annual report on March 24, 2026.
Drägerwerk AG & Co. KGaA Slides: Q4 2025
Drägerwerk AG & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 24, 2026.
Drägerwerk AG & Co. KGaA Slides: Investor presentation
Drägerwerk AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q3 2025
Strong order intake and sales growth drove robust earnings in the first nine months of 2025, with both Medical and Safety divisions contributing. Guidance was raised to the upper end of the range, though FX and regional headwinds remain risks.
Drägerwerk AG & Co. KGaA Quarterly report: Q3 2025
Drägerwerk AG & Co. KGaA has published its Q3 2025 quarterly earnings report on October 29, 2025.
Drägerwerk AG & Co. KGaA Slides: Q3 2025
Drägerwerk AG & Co. KGaA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 29, 2025.